Nanomedicine News and Research

RSS

T-rays are ideal for detecting early signs of melanoma

The technology that peeks underneath clothing at airport security screening check points has great potential for looking underneath human skin to diagnose cancer at its earliest and most treatable stages, a scientist said here today.

12 Sep 2013

Scientists use nanodiamonds to boost delivery of drug to leukemic cells

By binding multiple molecules of a common leukemia drug with nanodiamonds, scientists from the National University of Singapore (NUS) and University of California, Los Angeles (UCLA) managed to boost the delivery of the drug to leukemic cells and retain the drug within the cells to combat the cancer.

11 Sep 2013

New drug delivery system using NDs allows for direct application of chemotherapy to brain tumors

Researchers at UCLA's Jonsson Comprehensive Cancer Center have developed a new drug delivery system using nanodiamonds (NDs) that allows for direct application of chemotherapy to brain tumors with fewer harmful side effects and better cancer-killing efficiency than existing treatments.

10 Sep 2013

Researchers develop novel transparent skull implant that provides a window to the brain

A team of University of California, Riverside researchers have developed a novel transparent skull implant that literally provides a "window to the brain", which they hope will eventually open new treatment options for patients with life-threatening neurological disorders, such as brain cancer and traumatic brain injury.

4 Sep 2013

Smartphone-based portable device to conduct kidney tests invented at UCLA

A lightweight and field-portable device invented at UCLA that conducts kidney tests and transmits data through a smartphone attachment may significantly reduce the need for frequent office visits by people with diabetes and others with chronic kidney ailments.

26 Aug 2013

Study suggests silicon nanocrystals may be safe tool for diagnostic imaging in humans

Tiny silicon crystals caused no health problems in monkeys three months after large doses were injected, marking a step forward in the quest to bring such materials into clinics as biomedical imaging agents, according to a new study.

1 Aug 2013

Kala Pharmaceuticals to present preclinical data on mucosal-penetrating particle technology

Kala Pharmaceuticals, Inc., a leading developer of innovative products that rapidly and effectively penetrate the mucosal barrier to treat ocular diseases, announced today that Kala researchers will present preclinical data at the upcoming Controlled Release Society (CRS) 2013 Annual Meeting taking place July 21-24, 2013, in Honolulu, HI.

20 Jul 2013

New concept could improve cancer drug delivery

Researchers have developed a concept to potentially improve delivery of drugs for cancer treatment using nanoparticles that concentrate and expand in the presence of higher acidity found in tumor cells.

11 Jul 2013

CEA-Leti receives €1M from bpifrance to accelerate the development of liver-cancer detection system

CEA-Leti announced today €1 million in funding from bpifrance to accelerate preclinical development of a liver-cancer detection system called LipImage 815™.

4 Jul 2013

Researchers develop new drug delivery systems to treat cancer by blocking signaling receptor

A cardiac hormone signaling receptor abundantly expressed both in inflamed tissues and cancers appears to recruit stem cells that form the blood vessels needed to feed tumor growth, reports a new study by scientists at the University of South Florida Nanomedicine Research Center.

30 Jun 2013

Sorrento, IGDRASOL to present updates on IG-001 and IG-004 at joint meeting of CLINAM and ETPN

Sorrento Therapeutics, Inc. and IGDRASOL announced today that the companies will present updates of their analyses of proprietary late clinical stage paclitaxel formulations, IG-001 (Cynviloq) and IG-004 (TOCOSOL paclitaxel) at the joint meeting of the European Foundation for Clinical Nanomedicine and the European Technology Platform on Nanomedicine in Basel, Switzerland on June 23 - 26.

21 Jun 2013

Bioapplications of nanoparticles: an interview with Dr Catherine Berry, University of Glasgow

These particles are all classed as inorganic particles, which can all be utilised in biomedical applications. They differ in terms of their inherent material and size dependent physiochemical properties, for example, their optical and magnetic properties.

18 Jun 2013

Qiaobing Xu selected as Pew Scholar in Biomedical Sciences

Qiaobing Xu, assistant professor of biomedical engineering at Tufts University School of Engineering, was named a Pew Scholar in Biomedical Sciences by the Pew Charitable Trusts.

14 Jun 2013

White Paper provides recommendations to create ecosystem for use of Nanomedicine in Europe

The European Technology Platform on Nanomedicine and the NANOMED2020 project announce the publication of the White Paper on Contribution of Nanomedicine to Horizon 2020, the next European Framework Programme for Research and Innovation till 2020.

7 Jun 2013

New drug delivery system can help treat lung cancer

Researchers have developed a new drug delivery system that allows inhalation of chemotherapeutic drugs to help treat lung cancer, and in laboratory and animal tests it appears to reduce the systemic damage done to other organs while significantly improving the treatment of lung tumors.

23 May 2013

Magic bullet nanomedicine offers potential treatment option for Acute Lung Injury

Researchers at Queen's University Belfast have devised a 'magic bullet' nanomedicine which could become the first effective treatment for Acute Lung Injury or ALI, a condition affecting 20 per cent of all patients in intensive care.

15 May 2013

Protein tumor necrosis factor-alpha is a powerful weapon to control cancer

The protein tumor necrosis factor-alpha (TNF-alpha) is a powerful weapon in the arsenal to control cancer. Unfortunately, as is the case with many potent cancer therapies, the use of TNF-alpha as an anti-cancer therapy has been severely limited.

8 May 2013

BIND Therapeutics presents positive Phase 1 clinical study results for BIND-014 at AACR meeting

BIND Therapeutics, a clinical-stage biopharmaceutical company developing a new class of highly selective targeted and programmable therapeutics called AccurinsTM, announced today that positive Phase 1 clinical data for BIND-014, the company's lead drug candidate, were presented today in an oral presentation at the American Association for Cancer Research 2013 Annual Meeting.

10 Apr 2013

Sorrento Therapeutics, IGDRASOL to present updates on Cynviloq at Nanomedicine 2013 meeting

Sorrento Therapeutics, Inc. and IGDRASOL announced today that IGDRASOL will be presenting updates of its analysis of proprietary late clinical stage NBN-Pac formulations, namely IG-001 (Cynviloq) and IG-004 (a D-a-tocopheryl polyethylene glycol succinate (TPGS)-based paclitaxel formulation) at the annual Nanomedicine 2013 meeting in Barcelona, Spain (April 11th - 12th).

8 Apr 2013

New biodegradable nanoparticles deliver inflammation-resolving drugs to sites of tissue injury

A multicenter team of researchers, including scientists at Columbia University Medical Center (CUMC), Brigham and Women's Hospital (BWH), Mount Sinai School of Medicine, and Massachusetts Institute of Technology, has developed biodegradable nanoparticles that are capable of delivering inflammation-resolving drugs to sites of tissue injury.

20 Mar 2013